ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Lilly boosts immunotherapy pipeline with Armo BioSciences acquisition

The drug company will pay $1.6 billion to gain Armo’s IL-10 program

by Ryan Cross
May 10, 2018 | APPEARED IN VOLUME 96, ISSUE 20

 

In an effort to expand its immunotherapy pipeline, Eli Lilly & Co. will acquire the Redwood City, Cal­if.-based immuno-oncology company Armo BioSciences for $1.6 billion in cash.

Armo’s most advanced compound is pegilodecakin, which is being tested in a Phase III clinical trial involving people with pancreatic cancer, a condition resistant to many existing therapies. Armo has tested pegilodecakin in more than a dozen other kinds of cancer in earlier studies as well.

Pegilodecakin is a polyethylene glycol-modified interleukin-10 drug. IL-10 is a natural protein that normally exerts broad anti-inflammatory effects on the body. In fact, mice lacking IL-10 are prone to develop conditions such as inflammatory bowel disease. Since the goal of immunotherapy is to restore and supercharge immune cells’ abilities to infiltrate the immuno­suppressive environments of tumors, using IL-10 to suppress inflammation seems counterintuitive, especially since other immunotherapy programs are designed to promote inflammation near the tumor site.

Chronic inflammation is a risk factor for cancer, however, and mice without IL-10 develop tumors more easily than mice with a normal supply of the protein. When IL-10 is given to humans as a therapy, it causes activation and proliferation of a class of T cells important for attacking tumors.

Armo is also testing pegilodecakin alongside chemotherapy and other immuno-oncology drugs, including the anti-PD-1 checkpoint inhibitors Opdivo and Keytruda from Bristol-Myers Squibb and Merck & Co., respectively.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment